March 15, 2021
A federal judge in Massachusetts gave an initial nod to the proposed settlement of a trio of shareholder derivative suits against Acer Therapeutics Inc. that would see the company making a slate of corporate reforms to end allegations it misled investors about the prospects for a drug it was developing.
January 22, 2021
Shareholders behind litigation in three states accusing Acer Therapeutics Inc. of misrepresenting the potential for a U.S. Food and Drug Administration approval settled their lawsuits against the Massachusetts-based company in exchange for a slate of corporate reforms designed to improve its public disclosures, according to a Thursday filing.